Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3211 AL 3225

Aporphines and Alzheimer's Disease: Towards a Medical Approach Facing the Future

Nabavi SM, Uriarte E, Rastrelli L, Sobarzo-Sánchez E.

Curr Med Chem. 2019;26(18):3253-3259. doi: 10.2174/0929867325666180514102933.

A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease

Korabecny J, Spilovska K, Mezeiova E, Benek O, Juza R, Kaping D, Soukup O.

Curr Med Chem. 2019;26(30):5625-5648. doi: 10.2174/0929867325666180517094023.

Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease

Shi Y, Wang Y, Wei H.

CNS Neurol Disord Drug Targets. 2019;18(9):668-676. doi: 10.2174/1871527317666180619162649.

Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease

Talarico G, Trebbastoni A, Bruno G, de Lena C.

Curr Neuropharmacol. 2019;17(2):176-183. doi: 10.2174/1570159X16666180702144644.

Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease - A Literature Review

Basavan D, Chalichem NSS, Kumar MKS.

Curr Drug Targets. 2019;20(3):263-291. doi: 10.2174/1389450119666180813095637.

Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review

Alam J, Sharma L.

Curr Drug Targets. 2019;20(3):316-339. doi: 10.2174/1389450119666180820104723.

Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update

Hoskin JL, Al-Hasan Y, Sabbagh MN.

Nicotine Tob Res. 2019 Feb 18;21(3):370-376. doi: 10.1093/ntr/nty116.

Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update

Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, Ashraf GM, Ahmad M.

Curr Neuropharmacol. 2019;17(3):232-246. doi: 10.2174/1570159X16666180828100002.

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Cardoso BR, Roberts BR, Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ, Hare DJ, Bush AI.

Neurotherapeutics. 2019 Jan;16(1):192-202. doi: 10.1007/s13311-018-0662-z.

Alzheimer's Disease - Future Therapy Based on Dendrimers

Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutovа A, Baeesa SS, Avila-Rodriguez M, Ustyugov AA, Bachurin SO.

Curr Neuropharmacol. 2019;17(3):288-294. doi: 10.2174/1570159X16666180918164623.

Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?

Zholos AV, Moroz OF, Storozhuk MV.

Curr Mol Pharmacol. 2019;12(1):12-26. doi: 10.2174/1874467211666181012150847.

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial

Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, Marcal T, Solomon E, Boumis A, Bet A, Mennes M, van Oort E, Beckmann CF, Braithwaite SP, Jackson S, Nikolich K, Stephens D, Kerchner GA, Wyss-Coray T.

JAMA Neurol. 2019 Jan 1;76(1):35-40. doi: 10.1001/jamaneurol.2018.3288.

Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets

Gupta S, Singhal NK, Ganesh S, Sandhir R.

CNS Neurol Disord Drug Targets. 2019;18(3):172-184. doi: 10.2174/1871527317666181114163515.

Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications

Khoury R, Grossberg GT.

CNS Drugs. 2019 Jan;33(1):17-29. doi: 10.1007/s40263-018-0590-9.

Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease

Watt AD, Jenkins NL, McColl G, Collins S, Desmond PM.

J Alzheimers Dis. 2019;68(4):1311-1316. doi: 10.3233/JAD-180865.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias